MedTrace Logo

Trial of SAVVY Vaginal Gel and HIV in Nigeria

NCT00130078 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2142

Last updated 2005-09-26

No results posted yet for this study

Summary

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Conditions

  • HIV Infections

Interventions

DRUG

1.0% C31G SAVVY vaginal gel

Sponsors & Collaborators

  • FHI 360

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • Biosyn

    lead INDUSTRY

Principal Investigators

  • Paul Feldblum · FHI 360

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30

Countries

  • Nigeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130078 on ClinicalTrials.gov